Therapeutic potential of targeting prokineticin receptors in diseases. Vincenzi M, Kremic A, Jouve A, Lattanzi R, Miele R, Benharouga M, Alfaidy-Benharouga N, Migrenne-Li S, Kanthasamy AG, Porcionatto M, Ferrara N, Tetko IV, Désaubry L, Nebigil CG.  Pharmacol Rev. In press (2023).

Pressure Overload-Mediated Sustained PKR2 (Prokineticin-2 Receptor) Signaling in Cardiomyocytes Contributes to Cardiac Hypertrophy and Endotheliopathies. Demir F, Urayama K, Audebrand A, Toprak-Semiz A, Steenman M, Kurose H, Nebigil CG. Hypertension. 77: 1559-1570 (2021).

Prokineticin signaling in heart-brain developmental axis: Therapeutic options for heart and brain injuries. Désaubry L., Kanthasam AG., Nebigil CG.  Pharmacol Res. 160: 105190 (2020).

Prokineticin receptor-1 signaling inhibits dose- and time-dependent anthracycline-induced cardiovascular toxicity via myocardial and vascular protection. Gasser A., Chen Y-W., Audebrand A., Daglayan A., Charavin M., Escoubet B., Karpov P., Tetko I., Chan MWY., Cardinale D., Désaubry L., Nebigil CG. JACC CardioOncology, 1: 84-102 (2019).

The role of GPCR signaling in cardiac Epithelial to Mesenchymal Transformation (EMT).  Nebigil CG, Désaubry L. Trends Cardiovasc. Med. 2018; 29:200-204.

Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes. Neal M., Luo D., Harischandra D.S., Gordon R., Sarkar S., Jin H., Anantharam V., Désaubry L., Kanthasamy A., Kanthasamy A.Glia 66: 2137-2157 (2018).

A Prokineticin-Driven Epigenetic Switch Regulates Human Epicardial Cell Stemness and Fate. Qureshi R, Kindo M, Boulberdaa M, von Hunolstein JJ, Steenman M, Nebigil CG. Stem Cells. 2018; 36: 1589-1602.

Prokineticin receptor-1-dependent paracrine and autocrine pathways control cardiac tcf21+ fibroblast progenitor cell transformation into adipocytes and vascular cells.Qureshi R, Kindo M, Arora H, Boulberdaa M, Steenman M, Nebigil CG. Sci Rep. 2017; 7: 12804.

Prokineticin Is a New Linker between Obesity and Cardiovascular Diseases. Nebigil CG. Front Cardiovasc Med. 2017; 4:20.

Updates on Endothelial Functions of Proangiogenic Prokineticin. Nebigil CG. Hypertension. 2016; 68: 1091-1097.

Prokineticin receptor-1 signaling promotes Epicardial to Mesenchymal Transition during heart development. Arora H, Boulberdaa M, Qureshi R, Bitirim V, Gasser A, Messaddeq N, Dolle P, Nebigil CG. Sci Rep. 2016; 6: 25541.

Prokineticin receptor 1 is required for mesenchymal-epithelial transition in kidney development. Arora H, Boulberdaa M, Qureshi R, Bitirim V, Messadeq N, Dollée P, Nebigil CG. FASEB J. 2016; 30: 2733-40.

Can prokineticin prevent obesity and insulin resistance? Von Hunolstein JJ, Nebigil CG. Curr Opin Endocrinol Diabetes Obes. 2015; 22: 367-73.

Discovery and cardioprotective effects of the first non-peptide agonists of the G protein-coupled prokineticin receptor-1. Gasser A., Brogi S., Urayama K., Nishi T., Kurose H., Tafi A., Ribeiro N., Désaubry L., Nebigil CG. Plos One. 10: e0121027 (2015).

 Prokineticin receptor 1 as a novel suppressor of preadipocyte proliferation and differentiation to control obesity. Szatkowski C, Vallet J, Dormishian M, Messaddeq N, Valet P, Boulberdaa M, Metzger D, Chambon P, Nebigil CG. PLoS One. 2013; 8: e81175.

Prokineticin receptor-1 is a new regulator of endothelial insulin uptake and capillary formation to control insulin sensitivity and cardiovascular and kidney functions. Dormishian M, Turkeri G, Urayama K, Nguyen TL, Boulberdaa M, Messaddeq N, Renault G, Henrion D, Nebigil CG. J Am Heart Assoc. 2013; 2: e000411.

Prokineticin receptor 1 (PKR1) signalling in cardiovascular and kidney functions. Boulberdaa M, Urayama K, Nebigil CG. Cardiovasc Res. 2011; 92: 191-8.

Genetic inactivation of prokineticin receptor-1 leads to heart and kidney disorders. Boulberdaa M, Turkeri G, Urayama K, Dormishian M, Szatkowski C, Zimmer L, Messaddeq N, Laugel V, Dollé P, Nebigil CG. Arterioscler Thromb Vasc Biol. 2011;31: 842-50.

Divergent roles of prokineticin receptors in the endothelial cells: angiogenesis and fenestration. Guilini C, Urayama K, Turkeri G, Dedeoglu DB, Kurose H, Messaddeq N, Nebigil CG. Am J Physiol Heart Circ Physiol. 2010; 298: H844-52.

Prokineticin receptors in cardiovascular function: foe or friend? Nebigil CG. Trends Cardiovasc Med. 2009; 19: 55-60.

Transgenic myocardial overexpression of prokineticin receptor-2 (GPR73b) induces hypertrophy and capillary vessel leakage. Urayama K, Dedeoglu DB, Guilini C, Frantz S, Ertl G, Messaddeq N, Nebigil CG. Cardiovasc Res. 2009; 81: 28-37.

Prokineticin receptor-1 induces neovascularization and epicardial-derived progenitor cell differentiation. Urayama K, Guilini C, Turkeri G, Takir S, Kurose H, Messaddeq N, Dierich A, Nebigil CG. Arterioscler Thromb Vasc Biol. 2008; 28: 841-9.

The prokineticin receptor-1 (GPR73) promotes cardiomyocyte survival and angiogenesis. Urayama K, Guilini C, Messaddeq N, Hu K, Steenman M, Kurose H, Ert G, Nebigil CG. FASEB J. 2007; 21: 2980-93.